Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn $0.92 per share for the year, up from their previous estimate of $0.91. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share.
Fennec Pharmaceuticals Trading Down 7.6%
Shares of TSE:FRX traded down C$0.85 during trading on Wednesday, reaching C$10.30. 1,006 shares of the company were exchanged, compared to its average volume of 1,301. The business's fifty day simple moving average is C$8.40 and its 200-day simple moving average is C$8.57. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. Fennec Pharmaceuticals has a 12-month low of C$5.65 and a 12-month high of C$11.50. The firm has a market capitalization of C$198.63 million, a PE ratio of -174.48 and a beta of 0.25.
Insiders Place Their Bets
In related news, Director Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of C$7.46, for a total transaction of C$74,550.00. Also, Director Jeffrey Hackman acquired 15,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average cost of C$9.77 per share, with a total value of C$146,580.00. Insiders have sold 35,645 shares of company stock worth $316,021 in the last ninety days. 16.20% of the stock is owned by company insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
